Aldosterone receptor blockers in the treatment of heart failure

被引：1

作者：

Deswal A. ^{[1
]}

Yao D. ^{[1
]}

机构：

[1] Michael E. DeBakey VA Med. Center, Section of Cardiology, Houston, TX 77030

来源：

Current Treatment Options in Cardiovascular Medicine | 2004年 / 6卷 / 4期

关键词：

Aldosterone; Serum Potassium; Angiotensin Receptor Blocker; Main Drug Interaction; Eplerenone;

D O I：

10.1007/s11936-004-0034-3

中图分类号：

学科分类号：

摘要：

Heart failure is associated with neurohormonal activation, including activation of the renin-angiotensin-aldosterone system. Plasma aldosterone levels are elevated in patients with heart failure in spite of the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers because of angiotensin-independent stimuli for aldosterone production. In addition to its long recognized role in sodium retention, aldosterone has a number of other deleterious effects, including the increase in myocardial and vascular fibrosis and myocardial remodeling in patients with heart failure. Based on strong clinical trial data, low-dose aldosterone receptor blockers are recommended to improve morbidity and mortality in patients with severe chronic heart failure due to left ventricular systolic dysfunction and in patients with heart failure associated with left ventricular systolic dysfunction after acute myocardial infarction, and in patients already on standard therapy including ACE inhibitors (or angiotensin receptor blockers) and β blockers. In view of the potential for serious hyperkalemia with the use of aldosterone receptor blockers, it is essential to monitor serum potassium levels. Close adherence to the dosing regimens used in the clinical trials (RALES [Randomized Aldactone Evaluation Study] and EPHESUS [Eplerenone Post-AMI Heart Failure Efficacy and Survival Study]) is recommended. These agents should not be initiated in patients with severe renal insufficiency and closer monitoring is warranted in those with mild to moderate renal insufficiency or diabetes. Copyright © 2004 by Current Science Inc.

引用

页码：327 / 334

页数：7

共 27 条

[11]

Nicoletti A., Heudes D., Hinglais N., Et al., Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone, Hypertension, 26, pp. 101-111, (1995)

[12]

Suzuki G., Morita H., Mishima T., Et al., Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure, Circulation, 106, pp. 2967-2972, (2002)

[13]

Rocha R., Rudolph A.E., Frierdich G.E., Et al., Aldosterone induces a vascular inflammatory phenotype in the rat heart, Am. J. Physiol. Heart Circ. Physiol., 283, (2002)

[14]

Fraccarollo D., Galuppo P., Hildemann S., Et al., Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction, J. Am. Coll. Cardiol., 42, pp. 1666-1673, (2003)

[15]

Hayashi M., Tsutamoto T., Wada A., Et al., Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction, Circulation, 107, pp. 2559-2565, (2003)

[16]

MacFadyen R.J., Barr C.S., Struthers A.D., Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients, Cardiovasc. Res., 35, pp. 30-34, (1997)

[17]

Tsutamoto T., Wada A., Maeda K., Et al., Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure, J. Am. Coll. Cardiol., 37, pp. 1228-1233, (2001)

[18]

Barr C.S., Lang C.C., Hanson J., Et al., Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease, Am. J. Cardiol., 76, pp. 1259-1265, (1995)

[19]

Cicoira M., Zanolla L., Rossi A., Et al., Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure, J. Am. Coll. Cardiol., 40, pp. 304-310, (2002)

[20]

Sato A., Takane H., Saruta T., High serum level of pro-collagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients, Hypertens. Res., 24, pp. 99-104, (2001)

← 1 2 3 →